Buyback Announcements and News
12/20/2024
Insider transaction: Red Cat Holdings CFO Leah Lunger discloses sale of 524.8K shares - Form 4 ($10.75, 0.00)
- Lunger beneficially owns 322.5K shares of common stock, all direct, following the transaction.
12/20/2024
Arch Capital Group renewed share repurchase authorization of $1.0B - 8-K ($90.99, 0.00)
- On 20-Dec-24, Arch Capital Group Ltd. renewed its share repurchase authorization of $1.0B, which may be effected from time to time in open market or privately negotiated transactions.
12/20/2024
DocGo board approves extension of expiration date of current share repurchase program from 31-Dec-24 to 30-Jun-25 - 8-K ($4.50, 0.00)
- As previously disclosed, pursuant to the Repurchase Program, the company may purchase up to $26M in shares of the company's common stock. Other than the extension of the program's expiration date, no changes were made to the Repurchase Program.
12/20/2024
Colony Bankcorp authorized extension of stock buyback program - 8-K ($16.02, 0.00)
- On 18-Dec-24, the board of the company authorized the extension of the stock buyback program approved in October 2022, under which the company may repurchase up to $12M of its outstanding common stock.
- An extension was previously authorized by the board in March 2024 which extended the program through the end of 2024. This authorization extends the program until the end of 2025 but may be suspended, modified or terminated by the company at any time and for any reason, without prior notice.
12/20/2024
InterCure secures funding of NIS 66M to support recovery of Nir Oz facility ($1.34, 0.00)
- InterCure announced that further to the company's prior reports regarding the war-related damages and the reconstruction efforts of its facility in Kibbutz Nir Oz, the company was successful in obtaining funding commitments of NIS 66M (~$18.2M), which may increase to NIS 107M (~$29.8M).
- The funding includes a commitment by certain investors, including the company's CEO, Alexander Rabinovich, and two existing shareholders, Yaron Yakobi and Tzahi Hagag, who, as a result of the investment, will each hold more than 5% of the company's outstanding share capital to purchase ordinary shares of the company by way of a private placement.
- In the Private Placement, InterCure has agreed to issue to the Investors:
- (i) an aggregate of 7.3M ordinary shares of the company, at a purchase price of NIS 4.83 (~$1.34) per ordinary share, at a premium above the opening price of InterCure's ordinary shares on the Tel Aviv Stock Exchange on the morning of Monday, 16-Dec-24, which was NIS 4.81 per share and
- (ii) warrants to purchase up to an additional 7.3M ordinary shares of the company at an exercise price equal to NIS 5.70 (~$1.58), at an 18% premium above the opening price of InterCure's ordinary shares on the Determining Date, which may further increase the proceeds from the Private Placement up to a total of approximately NIS 77M (~$21.5M) if the Warrants are fully exercised in cash.
- In addition, the company received a binding commitment from one of the leading banks in Israel, to provide the company with a loan of NIS 30M (~$8.3M), for a period of up to 24 months. The Loan is subject to certain closing conditions, including closing the Private Placement.
- Under Israeli law, the company's Southern Facility, located in an area impacted by the terrorist attack and the war in Gaza, is entitled to full compensation for all direct and indirect damages incurred, including loss of profits.
- To date, the company has received advance payments totaling tens of millions of NIS from Israeli authorities as part of this compensation. These advances, which represent only a small portion of the company's total damages, have supported the initial phases of the ongoing restoration efforts. However, given the prolongation of the war and the fact that the last significant advance was received from the Israeli authorities only in April 2024, the current funding, will enable the company to successfully advance its recovery and restoration efforts without further delays.
- We expect that this funding will position the company to return to the growth and profitability rates it achieved prior to the war, during the year 2025. The company anticipates receiving additional substantial payments from the Israeli authorities, to which the company is entitled to, and is working closely with its professional advisors and the authorities to receive these payments.
12/20/2024
Golden Matrix Group resumes stock repurchase program with ~$4.958M available under current program ($1.98, 0.00)
12/20/2024
Insider transaction: Prelude Therapeutics CEO Krishna Vaddi discloses purchase of 106.9K shares - Form 4 ($0.89, 0.00)
- 100K shares were purchased directly, as well as 6.9K shares were purchased through Sidus Ventures LLC, of which Vaddi is the manager
- Vaddi beneficially owns 1.17M shares of common stock directly, as well as 1.65M shares indirectly, following the transaction.
12/20/2024
Sirius XM holder Berkshire Hathaway discloses buying 4.96M shares (yesterday post-close) ($20.58, 0.00)
- Berkshire Hathway beneficially owns 117.5M shares following the transaction.
12/20/2024
ECARX announces $20.0M share repurchase program ($1.71, 0.00)
- The company's board has authorized a share repurchase program under which the company may repurchase up to $20.0M of its ordinary shares until the close of business on 30-Sep-25, U.S. Eastern Time.
- The company plans to adopt and implement this share repurchase program in accordance with applicable rules and requirements under the Securities Exchange Act of 1934, as amended, and the company's insider trading policy.
- The company expects to fund the repurchases out of its existing cash balance.
12/20/2024
CCC board approves new $300M share repurchase authorization ($11.79, 0.00)
- CCCS announced that its board has approved a new share repurchase authorization to repurchase up to $300M of the company's outstanding common stock.